🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What’s wrong with this picture? Anyone? Anyone? DOCTOR Bronte Holt is also presenting. But she’s only a Lady Doctor who completely doesn’t need a title. #GENCA #everydaysexism

New research - Schulberg et al - Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn’s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial thelancet.com/journals/langa… #GITwitter #Crohns #IBD

1/ Join A/Prof David Gyorki at 2.30pm today (David Gyorki Peter Mac Cancer Centre) and a multidisciplinary panel of experts to explore the role the gut microbiome plays in disease, and how its composition can impact the outcomes of #immunotherapy in #melanoma patients Novartis

2/ Panel: Prof Jonathon Cebon, Prof Sammy Bedoui, Dr Miles Andrews, A/Prof Shahneen Sandhu, Rose Rocca, Dr Emily Wright, Melissa Sheldon Jonathan Cebon ONJ Cancer Research Institute Austin Health @BedouiSammy Doherty Institute University of Melbourne The Alfred Monash University A/Prof. Shahneen Sandhu Emily Wright @StVincentsMelb

The non-invasive multi-marker Endoscopic Healing Index (EHI) is showing good potential to be used as part of a strategy to monitor for post-operative #crohnsdisease recurrence. pubmed.ncbi.nlm.nih.gov/35689453/ Looking forward to seeing this develop.

Great news for future #IBD moms- Emily Wright shares that's it's safe to stay on vedolizumab and ustekinumab during pregnancy. #DDW2023

More confirmation of UST/VDZ safety in pregnancy. Infant levels mostly gone by 15 weeks. ⁦UST levels stable, VDZ levels drop but disease activity stable. nice work by ⁦Emily Wright⁩

Sunday Review #IBD101 Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn’s Disease Therapeutic Outcomes Assessed Clinically and Endoscopically doi.org/10.1093/ecco-j…

Thank you #AGW2023 for a great meeting. Lovely catching with friends and collaborators and hearing of the many exciting developments in our specialty.

pubmed.ncbi.nlm.nih.gov/37594369/ Proud of the collaboration Prometheus Laboratories. Important work in assisting with drug selection and personalisation of care in IBD.

Happy to share our case. We hope this adds to the discussion with pts of childbearing age who are candidates for JAKi with no other options than surgery. academic.oup.com/crohnscolitis3… Cynthia Seow Remo Panaccione, MD, FRCPC Kerri IBD YYC

Happy to share some great work by Ralley Prentice and PICCOLO-X. Maternal inflammation may be relevant. Reassuring re. TP use in pregnancy. Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease Is Associated With Exposu… pubmed.ncbi.nlm.nih.gov/38330216/

PICCOLO update. Screening for adverse 👶🏻 🧠 outcomes in IBD🤰 is feasible with 👶🏻 🧠 MRI + 📱 based movement assessments. Well controlled IBD in 🤰 did not ⬆️ abnormal 👶🏻 🧠 screening outcomes Rod Hunt Alicia Spittle Sally Bell Emma Flanagan Emily Wright Rimma Goldberg

A new and important study by Tom Goodsall Rob Bryant Christopher Ma MD MPH and many great colleagues from 🇦🇺 & 🌎 on #intestinalultrasound and reliability, cghjournal.org/article/S1542-… in CGH. I am delighted for the collaboration and to be involved as an IBUS InternationalBowelUS

An honour to present on behalf of Ralley Prentice & our team aiming to enhance care for 🤰 women with #IBD: Active disease on IUS in pregnancy associated with ⬆️ adverse pregnancy outcomes. We suggest #IUS monitoring in T1 and T2 and target IUS remission where possible #ECCO2025

Emily wright: current guidelines but need for better assessment and treatment options #ibd